7UIB image
Entry Detail
PDB ID:
7UIB
Keywords:
Title:
Crystal structure of BoNT/E receptor binding domain in complex with SV2, VHH, and sialic acid
Biological Source:
PDB Version:
Deposition Date:
2022-03-29
Release Date:
2023-04-05
Method Details:
Experimental Method:
Resolution:
2.77 Å
R-Value Free:
0.26
R-Value Work:
0.23
R-Value Observed:
0.23
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:VHH-G6
Chain IDs:A (auth: B), C (auth: E)
Chain Length:129
Number of Molecules:2
Biological Source:Vicugna pacos
Polymer Type:polypeptide(L)
Description:SV2
Chain IDs:B (auth: C), D (auth: F)
Chain Length:105
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Neurotoxin type E
Chain IDs:E (auth: D), F (auth: A)
Chain Length:407
Number of Molecules:2
Biological Source:Clostridium botulinum
Primary Citation
Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2.
Nat Commun 14 2338 2338 (2023)
PMID: 37095076 DOI: 10.1038/s41467-023-37860-8

Abstact

Botulinum neurotoxin E (BoNT/E) is one of the major causes of human botulism and paradoxically also a promising therapeutic agent. Here we determined the co-crystal structures of the receptor-binding domain of BoNT/E (HCE) in complex with its neuronal receptor synaptic vesicle glycoprotein 2A (SV2A) and a nanobody that serves as a ganglioside surrogate. These structures reveal that the protein-protein interactions between HCE and SV2 provide the crucial location and specificity information for HCE to recognize SV2A and SV2B, but not the closely related SV2C. At the same time, HCE exploits a separated sialic acid-binding pocket to mediate recognition of an N-glycan of SV2. Structure-based mutagenesis and functional studies demonstrate that both the protein-protein and protein-glycan associations are essential for SV2A-mediated cell entry of BoNT/E and for its potent neurotoxicity. Our studies establish the structural basis to understand the receptor-specificity of BoNT/E and to engineer BoNT/E variants for new clinical applications.

Legend

Protein

Chemical

Disease

Primary Citation of related structures